Biology subjects

Yeung, H. Y.

Publications and source records attributed to Yeung, H. Y..

8 recordsLinked to original sources

bioRxiv2026

Prey-specific toxins provide broad venom activity in cephalopods

Cephalopods are among the oceans most sophisticated predators that use camouflage, complex behaviors, and venom to subdue a wide range of prey. However, the functional role of venom across diverse prey remains poorly understood, particularly whether cephalopods deploy venom to capture fish. Through comprehensive transcriptomic profiling of venom glands, we identify toxins with molecular signatures of prey-specific adaptation, including a previously unrecognized family of peptide toxins, octotensins, that evolved through convergent evolution to mimic the vertebrate hormone neurotensin. Functional assays and cryo-electron microscopy demonstrate that octotensins potently activate fish and human neurotensin receptor 1, engage this target in a near-identical manner to the chordate hormone, and induce acute hypotension in rodents. Together, our findings demonstrate that cephalopods achieve broad venom activity through phylum-specific toxins, including those targeting fish, revealing an evolutionary strategy by which generalist predators can capture phylogenetically diverse prey. One-Sentence SummaryCephalopod venom comprises prey-specific toxins, including neurotensin-mimicking peptides that target fish.

systems biology↗

bioRxiv2026

Mimics of the chordate gut-brain hormone neurotensin in parasitic intestinal hookworms

Hookworms of the family Ancylostomatidae are intestinal parasites that infect hundreds of millions of people worldwide, contributing to malnutrition, anemia, and impaired development. While hookworms are known to secrete immunomodulatory molecules to evade host defenses, it has been unclear whether they also exploit host hormonal signaling. Here, we identify a previously unrecognized family of hookworm peptides, which we term ancylotensins. Ancylotensins share strong sequence similarity with the chordate hormone neurotensin, a key regulator of metabolism, gut-brain communication, and intestinal function. In vitro pharmacological assays, ex vivo gut contractility studies, and cryo-electron microscopy demonstrate that ancylotensins closely replicate both the structural and functional properties of mammalian neurotensin to modulate gut function. Furthermore, ancylotensins do not share common ancestry with chordate neurotensin and instead evolved independently via convergent evolution. These findings reveal the existence of gut peptide mimicry as a mechanism by which intestinal parasites can manipulate host physiology.

biochemistry↗

bioRxiv2025

Phylogenetic Diversity and Venom Gland Transcriptomics of Palauan Cone Snails (Conidae)

Cone snails (genus Conus Linnaeus, 1758) represent one of the most species-rich lineages of venomous marine snails, producing diverse and highly specialized toxins. While Conus diversity is particularly high in the Indo-Pacific, some regions, such as the archipelago of Palau, remain poorly studied. Here, we combine mitochondrial marker gene sequencing (COI, 12S, and 16S) and venom-gland transcriptomics to investigate the phylogenetic relationships and venom gene diversity of Palauan Conus species. We sampled 27 species, recovering mitochondrial sequences for 34-41 individuals per gene. Maximum-likelihood phylogenetic analysis revealed that most individuals group with known species, although several lineages show notable divergence from reference sequences. We additionally sequenced venom gland transcriptomes from 21 individuals representing 14 species, including three species for which no previous venom data exist. Comparative analysis showed largely consistent expression patterns at the superfamily level within species collected from different biogeographical regions, supporting conserved venom gene expression profiles. These results contribute foundational data for future studies of Conus evolution, biogeography, and toxin diversification in an underexplored biodiversity hotspot.

evolutionary biology↗

bioRxiv2025

Increased RAMP3 expression enhances GLP-1 mediated Glucose Stimulated Insulin Secretion in a Manner Dependent on Ca2+ Mobilisation

The targeting of the Glucagon-like peptide-1 receptor (GLP-1R) for diabetes and obesity is not a novel strategy, with recent therapeutics showing efficacy in weight loss and glycaemic control. However, they are also associated with side effects, including gastrointestinal disruptions and pancreatitis. Developing agonists with different signalling profiles, or that exert some tissue selectivity can circumvent these on-target, unwanted effects. Receptor activity-modifying proteins (RAMPs) offer the potential to do both, through modulation of agonist binding and signalling, as well as surface expression. The GLP-1R was found to interact with RAMP3, with the heterodimer able to bind agonist at the cell surface. RAMP3 expression biased the receptor towards Ca2+ mobilisation, away from the canonical cAMP-driven signalling. When examining G protein coupling, the interaction with RAMP3 reduced activation of the cognate Gs but increased secondary couplings to Gq and Gi. These increased couplings led to an elevation in glucose-stimulated insulin secretion when cells overexpressing RAMP3 were stimulated with GLP-1. A reciprocal effect was observed when looking at reduced expression of endogenous RAMP3, with a loss of sensitivity to GLP-1 in both glucose and insulin tolerance tests in a Ramp3 knockout mouse. The effects of this interaction can then inform selection of models and peptide design when targeting this receptor for therapeutic intervention. Significance StatementG Protein-Coupled Receptors, such as the Glucagon-Like Peptide-1 (GLP-1) Receptor are common drug targets, although not without side effects due to on-target, unwanted signalling outputs. This study identifies an interacting protein which alters its signalling to promote insulin secretion. This may improve the therapeutic potential of GLP-1 mimetics, enhancing effectual signalling over that associated with unwanted effects by directly targeting this receptor complex.

pharmacology and toxicology↗

bioRxiv2024

Venom-inspired somatostatin receptor 4 (SSTR4) agonists as new drug leads for peripheral pain conditions

Persistent pain affects one in five people worldwide, often with severely debilitating consequences. Current treatment options, which can be effective for mild or acute pain, are ill-suited for moderate-to-severe persistent pain, resulting in an urgent need for new therapeutics. In recent years, the somatostatin receptor 4 (SSTR4), which is expressed in sensory neurons of the peripheral nervous system, has emerged as a promising target for pain relief. However, the presence of several closely related receptors with similar ligand-binding surfaces complicates the design of receptor-specific agonists. In this study, we report the discovery of a potent and selective SSTR4 peptide, consomatin Fj1, derived from extensive venom gene datasets from marine cone snails. Consomatin Fj1 is a mimetic of the endogenous hormone somatostatin and contains a minimized binding motif that provides stability and drives peptide selectivity. Peripheral administration of synthetic consomatin Fj1 provided analgesia in mouse models of postoperative and neuropathic pain. Using structure-activity studies, we designed and functionally evaluated several Fj1 analogs, resulting in compounds with improved potency and selectivity. Our findings present a novel avenue for addressing persistent pain through the design of venom-inspired SSTR4-selective pain therapeutics. One Sentence SummaryVenom peptides from predatory marine mollusks provide new leads for treating peripheral pain conditions through a non-opioid target.

pharmacology and toxicology↗

bioRxiv2021

RAMPs regulate signalling bias and internalisation of the GIPR

Gastric inhibitory polypeptide (GIP) receptor is a class B1 GPCR, that responds to GIP and physiologically potentiates glucose-stimulated insulin secretion. Like most class B1 GPCRs, GIPR has been shown to interact with RAMPs, yet the effects of RAMPs on its signalling and trafficking remain poorly understood. We demonstrate that RAMPs modulate G protein activation and GIPR internalisation profiles. RAMP3 reduced GIPR Gs activation and cAMP production but retained GIPR at the cell surface, and this was associated with prolonged ERK1/2 phosphorylation and {beta}-arrestin association. By contrast, RAMP1/2 reduced Gq/11/15 activation of the GIPR. Through knockout mice studies, we show that RAMP1 is important to the normal physiological functioning of GIPR to regulate blood glucose levels. Thus, RAMPs act on G protein/{beta}-arrestin complexes, having both acute and chronic effects on GIPR function, while this study also raises the possibility of a more general role of RAMP3 to enhance GPCR plasma membrane localisation.

pharmacology and toxicology↗

bioRxiv2019

Promiscuous receptor activation mediates glucagonostatic effects of GLP-1(9-36) and GLP-1(7-36)

The incretin hormone glucagon-like peptide 1(7-36) (GLP-1(7-36)) stimulates insulin and inhibits glucagon secretion. The mechanisms by which GLP-1 suppresses glucagon release are unclear as glucagon-secreting -cells express GLP-1 receptors (GLP-1Rs) at very low levels. Here, we examine the underlying mechanisms. We find that both GLP-1(7-36) and its degradation product GLP-1(9-36) inhibit glucagon secretion at physiological (pM) concentrations. Whereas the effect of GLP-1(7-36) is sensitive to PKA inhibition, GLP-1(9-36) exerts its effect by a PKA-independent mechanism sensitive to pretreatment with pertussis. The glucagonostatic effects of both GLP-1(7-36) and (9-36) are retained in islets from Glp1r knockout mice but only GLP-1(9-36) remains glucagonostatic in the presence of the DPP-4 (the peptidase catalyzing the formation of GLP-1(9-36)) inhibitor sitagliptin. Glucagon receptor (GCGR) antagonism specifically prevents the inhibitory effects of GLP-1(9-36) whilst not affecting that of GLP-1(7-36). We conclude that GLP-1(7-36) and GLP-1(9-36) regulate glucagon secretion via interaction with GLP-1R and GCGR, respectively. HighlightsO_LIGLP-1(7-36) and GLP-1(9-36) inhibit glucagon secretion from alpha-cells C_LIO_LIGLP-1(7-36) and (9-36) retain glucagonostatic effect in Glp1r-/- islets C_LIO_LIGLP-1(7-36) and (9-36) activate distinct signal transduction mechanisms C_LIO_LIGLP-1(7-36) acts via GLP-1R and GLP-1(9-36) via GCGR C_LI

molecular biology↗

bioRxiv2019

Elevated intracellular cAMP concentration mediates growth suppression in glioma cells

Supressed levels of intracellular cAMP have been associated with malignancy. Thus, elevating cAMP through activation of adenylyl cyclase (AC) or by inhibition of phosphodiesterase (PDE) may be therapeutically beneficial. Here, we demonstrate that elevated cAMP levels suppress growth in C6 cells (a model of glioma) through treatment with forskolin, an AC activator, or a range of small molecule PDE inhibitors with differing selectivity profiles. Forskolin suppressed cell growth in a protein kinase A (PKA)-dependent manner by inducing a G2/M phase cell cycle arrest. In contrast, trequinsin (a non-selective PDE2/3/7 inhibitor), not only inhibited cell growth via PKA, but also stimulated (independent of PKA) caspase-3/-7 and induced an aneuploidy phenotype. Interestingly, a cocktail of individual PDE 2,3,7 inhibitors suppressed cell growth in a manner analogous to forskolin but not trequinsin. Finally, we demonstrate that concomitant targeting of both AC and PDEs synergistically elevated intracellular cAMP levels thereby potentiating their antiproliferative actions.

pharmacology and toxicology↗